Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification

Circulation

Volumn 109, Issue 8, 2004, Pages 990-996

  Camm, A John ^a,f   Pratt, Craig M ^b   Schwartz, Peter J ^c   Al Khalidi, Hussein R ^d   Spyt, Maria J ^d   Holroyde, Michael J ^d   Karam, Roger ^d   Sonnenblick, Edmund H ^e   Brum, Jose M G ^d  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PAVIA   (Italy)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiarrhythmia agents; Azimilide; Heart rate; Trials

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; STATINE DERIVATIVE; WARFARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; HIGH RISK PATIENT; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; THORAX PAIN; TORSADE DES POINTES; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; LIFE TABLES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUTROPENIA; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; RISK FACTORS; SURVIVAL ANALYSIS; TORSADES DE POINTES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 1442335812     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000117090.01718.2A     Document Type: Article

References (28)

1. Arora RB. Role of aldosterone in myocardial infarction. Ann N Y Acad Sci. 1965;118:539-554.
2. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;2:1313-1315.
3. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with evidence of heart failure. Lancet. 1993;342: 821-828.
4. Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. Circulation. 1997;96:122-127.
5. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
6. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
7. Pratt CM, Waldo AL, Camm AJ. Can antiarrhythmic drugs survive survival trials? Am J Cardiol. 1998;81:24D-34D.
8. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol Lancet. 1996;348:7-12.
9. The search for novel antiarrhythmic strategies: Sicilian Gambit. Eur Heart J. 1998;19:1178-1196.
10. Bigger JT, Fleiss JL, Kleiger R, et al. The relationship among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984;69:250-258.
11. Odemuyiwa O, Poloniecki J, Malik M, et al. Temporal influences on the prediction of postinfarction mortality by heart rate variability: a comparison with the left ventricular ejection fraction. Br Heart J. 1994;71: 521-527.
12. Hartikainen JE, Malik M, Staunton A, et al. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular and ejection fraction. J Am Coll Cardiol. 1996;28:296-304.
13. LaRovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation. 2001;103:2072-2077.
14. Malik M, Camm AJ, Janse MJ, et al. Depressed heart rate variability identifies post infarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol. 2000;35: 1263-1275.
15. Bilchick KC, Fetics B, Djoukeng R, et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol. 2002;90:24-28.
16. Davies MP, Freeman LC, Kass RS. Dual actions of the novel class III antiarrhythmic drug (NE-10064) on delayed potassium channel currents in the guinea pig ventricular sinoatrial node cells. J Pharmacol Exp Ther. 1996;276:1149-1154.
17. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064) a class III antiarrhythmic agent. Cardiovasc Drug Rev. 1997;15: 137-156.
18. Karam R, Marcello S, Brooks RR, et al. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol. 1998;81:40D-46D.
19. Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular arrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol. 2004;43:39-43.
20. Malik M, Cripps T, Farrell T, et al. Long-term spectral analysis of heart rate variability: an algorithm based on segmental frequency distributions of beat-to-beat intervals. Int J Biomed Comput. 1989;24:89-110.
21. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:649-653.
22. Collett D. Modelling Survival Data in Medical Research. London, UK: Chapman & Hall; 1994.
23. Cairns JA, Connolly SJ, Roberts R, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarization. CAMIAT. Lancet. 1997;349:675-682.
24. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction. EMIAT. Lancet. 1997;349:667-674.
25. Yap YG, Camm AJ. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs. Am J Cardiol. 1999;84:83R-89R.
26. Connolly SJ, Schnell DJ, Page RL, et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol. 2001;88:974-979.
27. Lehmann MH, Hardy S, Archibald D, et al. Sex differences in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2534-2541.
28. Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomized trial. Lancet. 2000;356:2052-2058.